835 related articles for article (PubMed ID: 26394161)
1. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Armstrong MJ; Hull D; Guo K; Barton D; Hazlehurst JM; Gathercole LL; Nasiri M; Yu J; Gough SC; Newsome PN; Tomlinson JW
J Hepatol; 2016 Feb; 64(2):399-408. PubMed ID: 26394161
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Armstrong MJ; Gaunt P; Aithal GP; Barton D; Hull D; Parker R; Hazlehurst JM; Guo K; ; Abouda G; Aldersley MA; Stocken D; Gough SC; Tomlinson JW; Brown RM; Hübscher SG; Newsome PN
Lancet; 2016 Feb; 387(10019):679-690. PubMed ID: 26608256
[TBL] [Abstract][Full Text] [Related]
3. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis.
Armstrong MJ; Hazlehurst JM; Hull D; Guo K; Borrows S; Yu J; Gough SC; Newsome PN; Tomlinson JW
Diabetes Obes Metab; 2014 Jul; 16(7):651-60. PubMed ID: 24962805
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
5. C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis.
Rahman K; Liu Y; Kumar P; Smith T; Thorn NE; Farris AB; Anania FA
Lab Invest; 2016 Aug; 96(8):895-908. PubMed ID: 27239734
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
7. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
9. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
[TBL] [Abstract][Full Text] [Related]
10. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
Matikainen N; Söderlund S; Björnson E; Pietiläinen K; Hakkarainen A; Lundbom N; Taskinen MR; Borén J
Diabetes Obes Metab; 2019 Jan; 21(1):84-94. PubMed ID: 30073766
[TBL] [Abstract][Full Text] [Related]
12. Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease.
Alvares D; Hoffman S; Stankovic B; Adeli K
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Mar; 1864(3):326-334. PubMed ID: 30578967
[TBL] [Abstract][Full Text] [Related]
13. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
[TBL] [Abstract][Full Text] [Related]
14. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
[TBL] [Abstract][Full Text] [Related]
15. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
[TBL] [Abstract][Full Text] [Related]
19. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
20. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
Barritt AS; Marshman E; Noureddin M
Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
